98%
921
2 minutes
20
Biotherapy offers a promising approach for treating a variety of diseases. However, the lack of advanced delivery systems remains a significant barrier to improve the efficacy, safety, and cost-effectiveness of biotherapeutics. The microneedle, as a minimally invasive drug delivery tool, has demonstrated considerable potential in biotherapeutic applications. Despite this promise, challenges remain in fabricating microneedles that effectively preserve the bioactivity of biotherapeutics. Emerging as a novel solution, cryomicroneedles (cryoMNs) employ cryogenically molded ice matrices that exploit phase-transition thermodynamics. The metabolic stasis induced by cryoimmobilization preserves biomolecular conformation and cellular viability. Moreover, the ice-reinforced architectures achieve an optimal balance between mechanical penetration capacity and post-insertion dissolution kinetics, overcoming the rigidity-flexibility trade-off in traditional dissolving microneedles. Current research prioritizes three breakthrough directions: material innovation for cryocompatible polymer-ice interfaces, cold-chain optimization strategies to enhance payload viability, and innovations in medical application scenarios. Notably, preclinical successes in regenerative tissue engineering and thermostable vaccine platforms highlight cryoMNs' potential to bridge precision medicine and global health equity. This review provides an overview of recent advancements in cryoMNs and discusses the potential challenges and future directions for the development of cryoMNs-mediated biotherapeutics delivery.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12362829 | PMC |
http://dx.doi.org/10.1002/smsc.202500009 | DOI Listing |
Mol Ther Nucleic Acids
September 2025
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran 1316943551, Iran.
Gene editing is a groundbreaking therapeutic approach that can potentially treat a broad spectrum of genetic and acquired diseases. This review highlights recent clinical trials employing advanced gene editing technologies such as CRISPR-Cas9, zinc-finger nucleases (ZFNs), and base editors across multiple disease areas including metabolic disorders, autoimmune diseases, muscular dystrophies, and inherited eye disorders. Central to the success of these therapies is the development of efficient and safe delivery systems, including lipid nanoparticles (LNPs), viral vectors (adenoviral and lentiviral), electroporation techniques, and virus-like particles (VLPs), which facilitate precise editing of target cells or .
View Article and Find Full Text PDF3 Biotech
September 2025
Manipal Centre for Biotherapeutics Research, Manipal Academy of Higher Education, Manipal, India.
Unlabelled: Glioblastoma (GBM) is the most aggressive primary brain tumor in adults and is characterized by rapid growth, diffuse infiltration, and resistance to conventional therapies. This review explores pathophysiology, molecular mechanisms, and therapeutic advancements of GBM. GBM is highly heterogeneous and can be classified into molecular subtypes based on genetic and epigenetic alterations, influencing patient prognosis and treatment response.
View Article and Find Full Text PDFACS Appl Mater Interfaces
September 2025
Tim Taylor Department of Chemical Engineering, Kansas State University, Manhattan, Kansas 66506, United States.
Stimuli-responsive hydrogels that provide controlled degradation can be used as bacteria delivery systems for advanced therapeutic applications. Here, we report the first use of photodegradable hydrogels as materials that can direct bacterial movement, tune mean bacteria speed, and control bacteria delivery through spatiotemporal control of degradation. Hydrogels were formed using base-catalyzed Michael addition reactions between photodegradable poly(ethylene glycol) (PEG) -nitrobenzyl diacrylate macromers and PEG tetra-thiol cross-linkers within microfluidic channels.
View Article and Find Full Text PDFActa Biomater
August 2025
Department of Cardiovascular Medicine, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA; Physiology and Biomedical Engineering, Center for Regenerative Biotherapeutics, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA. Electronic address:
Background Myocardial infarction leads to irreversible cardiomyocyte loss and adverse ventricular remodeling, often culminating in heart failure. Transplantation of functional cardiac patches offers a promising avenue for myocardial repair, yet current delivery methods typically require open-chest surgery and suturing of the graft, limiting their applicability in patients with severe heart failure. Methods We developed an engineered heart tissue composed of human induced pluripotent stem cell-derived cardiomyocytes, endothelial cells, and fibroblasts seeded on a durable, flexible scaffold.
View Article and Find Full Text PDFBiomater Sci
August 2025
Robert E. Fischell Institute for Biomedical Devices, 8278 Paint Branch Drive, College Park, MD 20742, USA.
Autoimmune disease occurs when immune cells mistakenly identify specific molecules, termed antigens, on healthy cells. There are no cures for these diseases, and existing treatments - including monoclonal antibodies - do not specifically target dysfunctional cells. These challenges have motivated interest in therapies that could achieve antigen-specific immune tolerance.
View Article and Find Full Text PDF